Atrial fibrillation
Conditions
Interventions
Rivaroxaban:?
Dabigatran:?
Sponsors
The Fifth People's Hospital of Shanghai
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Nonvalvular atrial fibrillation patients aged 18-100 years who take rivaroxaban or dabigatran etexilate 2. Signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with drug allergy or lactose allergy; 2. Patients receiving immunosuppressive drugs or low molecular weight heparin anticoagulant drugs; 3. Bleeding tendency, blood disease platelet count> 400 x 10^9 / L or 169 or <100 g / L; 4. History of peptic ulcer; 5. Malignant tumor, severe dysfunction or failure of multiple organs such as heart, liver and kidney; 6. Neurological diseases such as epilepsy; 7. The anticoagulant drugs were used together, including antiplatelet drugs, heparin, low molecular weight heparin, warfarin, non-vitamin K-dependent oral anticoagulant drugs, such as dabigatran, apixaban, etc .; 8. Patients taking Chinese patent medicine for promoting blood circulation and removing blood stasis at the same time.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of bleeding;Incidence of thrombosis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inhibition of FXa;Thrombin generation;PT; | — |
Countries
China
Contacts
Public ContactYan Yu
The Fifth People's Hospital of Shanghai
Outcome results
None listed